Regis University

ePublications at Regis University
All Regis University Theses

Fall 2015

Prick Testing in Children
Elizabeth Ann Esterl
Regis University

Follow this and additional works at: https://epublications.regis.edu/theses
Part of the Medicine and Health Sciences Commons
Recommended Citation
Esterl, Elizabeth Ann, "Prick Testing in Children" (2015). All Regis University Theses. 691.
https://epublications.regis.edu/theses/691

This Thesis - Open Access is brought to you for free and open access by ePublications at Regis University. It has been accepted for inclusion in All Regis
University Theses by an authorized administrator of ePublications at Regis University. For more information, please contact epublications@regis.edu.

Regis University
Rueckert-Hartman College for Health Professions
Capstone/Thesis

Disclaimer
Use of the materials available in the Regis University Capstone/Thesis Collection
(“Collection”) is limited and restricted to those users who agree to comply with
the following terms of use. Regis University reserves the right to deny access to
the Collection to any person who violates these terms of use or who seeks to or
does alter, avoid or supersede the functional conditions, restrictions and
limitations of the Collection.
The site may be used only for lawful purposes. The user is solely responsible for
knowing and adhering to any and all applicable laws, rules, and regulations
relating or pertaining to use of the Collection.
All content in this Collection is owned by and subject to the exclusive control of
Regis University and the authors of the materials. It is available only for research
purposes and may not be used in violation of copyright laws or for unlawful
purposes. The materials may not be downloaded in whole or in part without
permission of the copyright holder or as otherwise authorized in the “fair use”
standards of the U.S. copyright laws and regulations.

Reducing Variability Among Multiple Operators Using a Single Technique and Device for Skin
Prick Testing in Children
Elizabeth Ann Esterl
Submitted in partial fulfillment of the Doctor of Nursing Practice Degree
Regis University
December 02, 2015

Copyright Page
Copyright © 2014 Elizabeth Ann Esterl. All rights reserved. No part of this work may be
reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic,
mechanical, photocopying, recording or otherwise, without the author’s prior written permission.

i

Executive Summary
Capstone Project Title
Reducing Variability Among Multiple Operators Using a Single Technique and Device for Skin
Prick Testing in Children
Problem
The variability in performance among skin prick test (SPT) operators who performed the twist
technique versus the prick technique was raised within the Pediatric Program at the Study Site.
Confidence in the SPT results was threatened, treatment plans were delayed and diets remained
restricted.
Purpose
This Doctor of Nursing Practice (DNP) Capstone Project was designed to identify a single device
and technique that could be used at the facility to reduce variability, increase reliability, and
standardize the skin prick test procedure using a single technique and device within the
institution. This inexpensive test has the potential to yield enormous results at a single visit and
dictate life saving treatment, which is patient specific.
Research Study Objectives
The PICO (Population, Intervention, Comparison, Outcome) research question asked: (P)
Among children ages 1 year through 16 years receiving skin prick testing for diagnosis and
treatment of their allergic disease, (I) does the Quintip device puncture technique or Duotip
device twist technique (C) when compared to the Duotip prick technique (O) decrease variability
and increase reproducibility of results when conducted by multiple operators? The Capstone
Project successfully identified a single technique and device to be used by multiple operators to
provide high quality, reliable, and valid allergy skin testing results for at-risk patients.
Research Methods and Procedures
This DNP Capstone Project was a prospective, double-blind clinical trial using a convenience
sample in which pediatric research participants underwent SPT in a single session, with a single
operator using the Duotip twist and Quintip puncture techniques as compared to the Duotip
prick/lift technique.
Study Results
Comparing results between the three techniques and two devices, the Quintip twist method was
most sensitive (97%) as compared to the punch technique (86%) and prick/lift technique (89%).
Only 2.8% of those tested using the twist technique produced false negative responses to
histamine as compared to 14% (Quintip punch) and 11.1% (Duotip prick/lift).
Implications for Practice and Future Research
As new SPT technique and devices are introduced, ongoing research will be necessary to
evaluate variability and respoducibility among operators, to ensure improvements in diagnosis
and treatment food, drug and environmental allergies can be achieved.
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Reducing Variability Among Multiple Operators Using a Single Technique and Device for Skin
Prick Testing in Children
The United States Department of Health and Human Services- National Center for Health
Statistics (2013) reported a significant increase in the prevalence of food allergies in children
under the age of 18 years living in the United States during 2009-2011 as compared to 19972009. Skin prick testing has been used as a diagnostic tool since first described in the literature in
1873 when Dr. Charles H. Blackley scratched the skin on the forearm with a lancet and wet lint
saturated in grass pollen to diagnose chronic allergic rhinitis when a whealing response occurred
at the site (Krau and McInnis, 2010). This inexpensive, minimally invasive test can be conducted
in an outpatient office setting and is highly dependable when performed correctly (Cox et al.,
2008). However, if not performed correctly false positive and false negative results can occur
and treatment plans may have life threatening consequences. The purpose of this research study
aimed to identify the single skin prick test technique and device that allowed for the greatest
reproducibility and decreased variability among multiple operators performing skin prick test
procedure in the pediatric population at the study site.
Problem Recognition and Definition
Background and Significance of Problem
At the study site, medical providers evaluate and treat pediatric patients with a variety of
allergic, rheumatologic and immunologic disorders of childhood including pediatric asthma,
exercise-induced asthma, hives, allergies, food allergy, stinging insect allergy, anaphylaxis,
atopic dermatitis, immunodeficiency, recurrent infection, chronic cough, vocal cord dysfunction,
and illnesses which may complicate chronic allergic disease such as gastroesophageal and
laryngopharyngeal reflux (NJH, 2013). The study site brings together a team of America's best
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and highly skilled pediatric physician specialists, nurses, dietitians, psychosocial clinicians, and
ancillary team members. The comprehensive team approach is designed to provide accurate
diagnosis, develop individualized treatment plans, and deliver in-depth education to address the
specific needs and goals of each patient.
A common diagnostic procedure performed during the initial evaluation and on-going
follow-up care is the skin prick test. This test involves placing allergen solutions on the skin and
then pricked using a disposable device. The results of the SPT provide valuable information used
to confirm diagnoses and develop treatment plans (Cox et al., 2008). According to Cox (2008),
the SPT remains the preferred diagnostic technique for allergy because results are quickly
available, allows for evaluation of multiple allergens at a single office visit, and has a good
correlation to in vitro (serum IgE) testing. Visually, the SPT can provide a graphic representation
of the sensitivity for the allergen as compared to the saline and histamine controls. In addition,
less common allergens, such as local fruits and vegetables or certain brand name medications,
can be specifically tested using the SPT technique when no specific IgE antibody serum
measurements are available (Heinzerling et al., 2013).
The United States Joint Council of Allergy, Asthma and Immunology (2013) and the
European Academy of Allergy and Clinical Immunology (2013) highly recommend
percutaneous SPT as the primary tool for diagnosing allergic disease. Skin prick testing is a key
test in identifying allergens causing allergic symptoms, prescribing immunotherapy treatment,
and defining avoidance diets. As a result, physicians and health care providers must be confident
in the SPT results as they construct their medical diagnoses and treatment recommendations.
False positive findings may occur if the operator presses the SPT device too hard against the
skin, causing erythema from technique versus true allergic response to antigen (Carr, W. et al.,
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2005). On the other hand, the operator may not press the SPT device hard enough against the
skin so the antigen cannot penetrate the epidermis, leading to a false negative finding. Patients
may end up being exposed to allergens that they are highly allergic to and subsequently have life
threatening reactions when allergens are unknowingly introduced.
New SPT devices continue to be developed including multihead devices, which allow for
application of several antigens simultaneously; however, these have been difficult to use in the
pediatric population at the study site. Children have a tendency to move unpredictably during the
procedure and multihead devices can cause variation in penetration of allergens across the
placement region on the back (Carr, 2005). Locally, the preferred single head tool is the Duotip
device using the prick-lift technique and the twist technique. However, for this DNP Capstone
Research Project, the researcher also used the single head Quintip device employing the punch
technique to assess reproducibility and variability among multiple operators.
In Fall 2013, the health care team at the study site noted increased variability of SPT
results among multiple operators. Before permitted to conduct the SPT procedure at the facility,
Certified Nursing Assistants and Registered Nurses had to successfully pass a written test and
demonstrate performance competency using their technique choice and read/record results with
100% accuracy. When concern about the SPT was raised at the facility, data was collected
including the technique each operator used, the number of previous tests performed, and the date
initial SPT education and training were completed. Results revealed the operators were trained
and deemed competent on one SPT technique but now were using another technique. Placement
of allergens on skin varied between operators and reading of results varied up to three minutesfrom 15 to18 minutes (Esterl, 2013). Immediate actions to increase the reliability and reduce
variability of results included repeat education and training for all operators before further SPT

4
was permitted, significantly limiting the number of operators performing the SPT procedures,
and restricting the technique to the twist technique using the Duotip device.
This DNP Capstone Research Project aided in identifying the single technique and device
needed to further limit variability and increase reliability of the SPT results when conducted on
children by multiple operators at the study site. According to the Allergy Diagnostic Practice
Parameter (Bernstein, 2008), "The reliability of prick/puncture tests depends on the skill of the
tester, the test instrument, color of the skin, skin reactivity on the day of the test, potency, and
stability of the reagents"(p 56). Health care providers must be confident in the results of the SPT
to assist in the diagnoses of food, environmental and drug allergies and develop a trustworthy
treatment plans for pediatric patients seen at the facility.
Statement of the Research Problem
Increased variability in SPT results was noted by the medical providers at the facility
when multiple operators conducted the SPT using the twist and prick techniques. Confidence in
the SPT results was threatened, treatment plans were delayed and diets remained restricted. The
goal of this DNP Capstone Research Project was to identify a single technique and device to
standardize the SPT procedure, reduce multiple operator variability and improve reproducibility
among the pediatric patients seen at the study site.
Statement of the Research Study Purpose and Aims
The purpose of this research study was to compare the variability of Skin Prick Test
(SPT) results of the Duotip twist and Quintip puncture techniques as compared to the Duotip
prick/lift technique when carried out on the backs of the pediatric participants by multiple
operators. Specifically, this Doctor of Nursing Practice (DNP) Capstone Research Project was
intended to evaluate reliability and variability of the SPT techniques and devices used by
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multiple operators in order to identify the superior single technique and device to be use by all
operators at the study site. With these results, physicians will be able to make accurate diagnoses
and treatment care plans for their highly allergic pediatric patients.
Aims related to SPT techniques and devices included:
1. To determine the variability of each SPT technique and device using multiple operators.
2. To determine the reliability of results using multiple operators and different SPT
techniques and devices.
3. To determine the single SPT technique and device to be used by all operators in the study
site
Literature Review/ Selection Process/ Summary
The focus of the systematic literature review was to assess the use of single-head SPT
devices and variability of results when performed by multiple operators in the pediatric
population. Six electronic databases searched included: PubMed, ClinicalTrials.Gov, CINAHL,
National Center for Biotechnology Information, Cochrane Database of Systematic Reviews
(CDSR) and Database of Abstracts for Review of Effectiveness (DARE). Initial searches were
restricted to English language articles published between 2002-2013. However, dates were
expanded to 1980-2013 to increase the number of research studies and reports used to confirm
previously published research on the SPT techniques and devices, regardless of the age of
participant. Searches included research conducted in the United States and throughout Europe as
long as it met all other criteria.
The terms used in the database searches included: food allergy, immunoglobulin E, SPT,
children, operator variability, allergy, sensitization, food allergens, eosinophil esophagitis,
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allergies, Type I, diagnostic test asthma, Duotip, Lancet, Quintip, and oral food challenges. The
search resulted in 30 reports as follows:


1

Cochrane systematic review

The Cochrane systematic review included electronic searches of PubMed, Cochrane
Database of Systematic Reviews, Cochrane Database of Abstracts of Review and Effect, and
Cochrane Central Register of Controlled Trials. Searches were limited to English language
articles indexed between January 1988 and September 2009. A total of 12378 citations were
identified and two investigators reviewed 72 citations independently, using the AMSTAR
criteria, the quality of the studies using the QUADAS criteria relevant to food allergy, and the
quality of the randomized controlled studies using the Jadad criteria (Chafen et al., 2010).


13

Well-designed randomized controlled adult trials



10

Well-designed controlled adult trials without randomization
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Evidence from systematic reviews of descriptive or qualitative studies

A review of the 30 reports revealed the use of SPT as the primary diagnostic tool for
allergy evaluation. However, this review revealed only one study that focused specifically on
children (Illi et al., 1998) and one study that included adults and children that compared SPT
with another diagnostic tool to identify and treat allergies in patients, but did not address operator
variability or reproducibility (Mehl, Niggemann, Keil, Wahn, & Beyer, 2012). Illi et al., (1998)
examined the variability of SPT testing performed by four different operators on 28 pediatric
subjects ages 6 years to 14 years. Researchers tested 16 children using the multihead device and
lancet on the forearm and found the lancet to be superior with operator reproducibility. The
remaining children were only tested with one device, 11 children were tested with the multihead
device and one child was tested was the lancet. Illi et al., (1998) noted "the skin prick tests
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applied by the four fieldworkers resulted in small, by statistically significant differences in their
outcomes" (pg. 357, para 1). This was the only study found during the review process that
focused specifically on multiple operator variability and reproducibility when performing SPT
on the pediatric population.
The remaining studies and reports from this systematic review focused on the adult
population, which served to inform this DNP Capstone Research Project. Studies comparing the
performance of commonly used SPT devices and techniques to achieve reproducible results
revealed significant differences when the SPT was conducted on the forearms and backs of the
adult participants (Carr, Martin, Howard, Cox, & Borish, 2005; Corallino, Nico, Kourtis,
Filomena Caiaffa, & Macchia, 2007; Masse et al., 2011; Werther et al., 2012; Nelson,
Kolehmainen, Lahr, Murphy, & Buchmeier, 2004; Nelson, Rosoniec, McCall, & Ikle, 1993).
However, the sample sizes in all of these studies were small, ranging from 12 to 22 adult
participants.
Four research studies on adults were completed (Nelson, Knoetzer, & Bucher, 1997;
Nelson, Kolehmainen, Lahr, Murphy, & Buchmeier, 2004; Nelson, Lahr, Buchmeier, &
McCormick, 1998; Nelson, Rosoniec, McCall, & Ikle, 1993) between 1993 and 2004 and
included 53 adult subjects enrolled in three SPT device comparison studies evaluating quality,
reproducibility, patient acceptance and one clinical study evaluating the distance between SPT
sites and the quality of allergen extracts with 79 adult subjects. These studies reported that the
SPT results varied greatly based on the SPT device used to conduct the test as depicted by the
size of reactions to the positive (histamine) and negative (glycerol-saline) control solutions. The
investigators recommended that operators be competency tested with the SPT devices to
establish testing baseline before allowing performance in the clinical setting. Furthermore,
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Nelson, Rosoniec, McCall, & Ikle (1993), reported the greater the trauma from the SPT device,
the larger the reaction to the histamine or allergan and the greater likelihood of a whealing
reaction and less likelihood of a false negative reaction. In addition, single and multihead devices
displayed a consistent and significant trend for larger wheals when performed lower on the back
and are unlikely to cause a false positive reaction when placed apart at least 2cm from another
prick site (Nelson, Knoetzer, & Bucher, 1997).
Carr et al., (2005) enrolled 20 adult subjects (13 subjects completed the study) into a
study comparing the performance of four multihead SPT devices and four single-head SPT
devices performed by a single operator and found significant differences between the two types
of devices (p<0.008), with multihead devices demonstrating the greatest variability and more
painful as compared to the single head devices. Skin prick test reactions using the multihead
devices were larger when tested on the back as compared to the single head devices with larger
reactions on the forearm.
In a study of 22 adults comparing the reproducibility and sensitivity of four SPT
instruments with the use of a positive control, Masse et al., (2011) calculated interpatient and
intrapatient reproducibility between each technique and found the 23G intravenous (IV) needle
and metal lancet were superior (p < 0.01) when compared to the two Stallerpoint and
Stallergenes prick lancet and methods.
Werther et al. (2012) reported in a research study that SPT results carried out by eight
operators using four different single-head devices. The researchers concluded that the lancet and
Quintip SPT devices using the punch technique had less variability among multiple operators
than those using the prick technique with the Greer Pick and Feather Lancet. However, their
sample size was small, five subjects in total and conducted with healthy adult volunteers.
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Regardless of the SPT device used, studies reported that the SPT caused minimal
discomfort, offered a high yield of information, but had significant variability dependent on
operator education and training (Carr, Martin, Howard, Cox, & Borish, 2005; Corallino, Nico,
Kourtis, Filomena Caiaffa, & Macchia, 2007; Masse et al., 2011; Nelson, Lahr, Buchmeier, &
McCormick, 1998; Werther et al., 2012).
In 2008, the American College of Allergy, Asthma and Immunology (ACAAI) and the
American Academy of Allergy, Asthma and Immunology (AAAAI) developed a task force
charged with developing the Allergy Diagnostic Practice Parameters (Cox et al., 2008). The
guidelines offered a comprehensive review of diagnoses, tests, and procedures, and expected
results for healthcare professionals caring for patients with allergic diseases for infants, children,
and adults. The updated information included SPT technique instructions and suggested
proficiency testing and quality assurance techniques for prick and puncture SPT (Cox et al.,
2008).
Based on the review of the literature, there was an identified need for research that
focused on SPT testing in the pediatric population. Therefore, this DNP Capstone Research
Project aimed to contribute to understand of SPT testing in children and improve the quality and
outcomes of care for the pediatric population.
Theoretical Foundation for Study
Nursing is an important part of the study site and directed to serve the health care needs
of children and their families. A general understanding of theoretical foundation and how
theories impact evidence-based practices were essential in the success of this research project.
Change theory. A theory of change provided the framework to move from one point to
another to achieve a goal. It differed from other theories by:
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Showed a pathway which time points and associated actions were needed to achieve
goals



Underlying assumptions were required, tested, and measured



Changed the way of thinking from what was currently being done to what was wanted to
be achieved
Kurt Lewin's three-step change theory. Universally, Lewin is known as the founder of

modern psychology and pioneered the use of experimentation in testing the change hypothesis
(Greathouse, 1997). In 1947, Kurt Lewin introduced the three-step change model. Lewin stressed
the importance of not only defining the goals of the change, but also including supportive
objectives to achieve during the change process to break the emotional bond noted at the initial
starting point. The three-step change model of Lewin's includes:
1. Unfreezing- The step is achieved by directing behavior away from the status quo,
promote positive force that will facilitate change through trust and recognition, and
actively participate in brainstorming solutions to achieve change (Lewin, 1947).
2. Movement- Create movement by changing the status quo. This can be accomplished by
providing new perspective with beneficial solutions, working together towards the new
common goal and leadership supporting the change.
3. Freezing- The third step reinforces the new behaviors and values that have been
integrated into the community. The driving forces of change and the restraining forces are
now stabilized and the combined forces are stronger. New policy and procedures
formalize the new process.
Lewin's contribution to the DNP Capstone Research Project. Health care providers at
the study site conducted SPT using the Duotip device and prick technique for over 25 years.
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Within the department, a single Certified Nursing Assistant conducted a majority of the
procedures ordered by the physician specialists for the pediatric patients. Over the last two years,
additional staff members were trained using the twist technique. The health care providers
expressed concern that results had increased variability when using the twist technique- more
specifically a higher incidence of erythema and increased false positive and false negative
results. Lack of confidence in results was further accentuated when multiple trained operators
conducted the SPT on the highly allergic pediatric patients.
The first step in Lewin's Change Theory was to change the status quo. This DNP
Capstone Research Project aimed to set a new goal and identify a single device and technique to
standardize the SPT procedure at the facility. This step required unfreezing the current mindset
by providing a feasible research opportunity, actively listening to the healthcare providers'
concerns, and allowing input for possible device options. Literature reviews and conversations
with manufacturers provided a third technique to investigate the Quintip puncture technique.
Movement was the second step in Lewin's Change Theory. This step included
implementing the study, enrolling participants and collecting data for analysis. The author
worked closely with the healthcare providers, operators, and other support members to discuss
daily activities and reassess goals dependent on data collected.
The last step in Lewin's Change Theory was freezing the change once the new goal was
attained. Communication of results, training, and educating the healthcare team were mandatory
to solidify the new process. Updating the current policies and procedures with the new
information reinforced that positive change occurred.
Lewin's Change Theory identified the necessary steps to define the status quo and the
steps to achieve a new goal through change in practice through evidence-based research. Change

12
was easier to accept when team members were involved in every aspect of the change process,
objectives were clear, and roles defined. Because the three steps of the Change Theory were
followed sequentially with buy in from the team members, positive change occurred.
Research Study Objectives
Study Research Question in PICO Format
The PICO (Population, Intervention, Comparison, Outcome) research question that
served as the focus of the study was defined in Table 1.
Table 1. PICO Question
P Population of Interest

I

Intervention of Interest

C Comparison of Interest
O Outcome of Interest

Among children ages 1 year to 16 years receiving skin
prick testing for diagnosis and treatment of their
allergic disease,
does the Quintip device puncture technique or Duotip
device twist technique
compare to the Duotip prick technique
decrease variability and increase reproducibility of
results when conducted by multiple operators?

Study Hypotheses
The following hypotheses were tested in this study:
1. Each of the three SPT techniques- Quintip device puncture technique, Duotip device
twist technique, and the Duotip prick technique- produce a positive wheal > 3mm to the
positive control of histamine on the back of the pediatric research participant.
2. Variability in SPT results was greatest using the Duotip prick technique among multiple
operators.
3. Variability in SPT results was the least using the Quintip device puncture technique,
regardless of operator change.
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4. The Quintip puncture technique was highly reproducible as compared to the Duotip prick
and twist techniques.
Definitions of Study Variables
1. Quintip Device- Manufactured by Hollister-Stier Laboratories in Spokane, Washington
and previously reported by the research of Carr et al., (2005) to have low variability in
results and high sensitivity and specificity.
2. Duotip Device- Manufactured by Lincoln Diagnostics in Decatur, Illinois and previous
research conducted by Corder, W., Hogan, M., and Wilson, N. (1996) revealed that the
bifurcated needle of the Duotip-Test device using the prick/lift technique had
significantly smaller histamine wheal and erythema responses than Duotip-Test twist
techniques (P < .05). The Duotip twist technique produced significantly larger wheals
(mean 1.1 mm, P < .001) to saline than the prick/lift technique.
3. Concomitant Medications- normal therapeutic doses may suppress SPT results and alter
variability.
4. Allergen Extract- can contain proteins that can induce allergic symptoms with exposure.
The end product is a complex mixture of the diluents or solvents, additives, preservatives,
and other components of the raw material that survive the manufacturing process. The
extract must be used before the expiration date or variation in expected SPT results can
occur.
5. Storage of Extracts- should be stored at 4° C to reduce the rate of potency. Extracts
beyond the expiration date should to be discarded. Expired extracts could lead to a
variation in SPT results.
6. Distance of Placement on Body Surface- between two SPT should be > 3 cm to avoid
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false positive reactions due to direct contamination of a nearby test or secondary to an
axon reflex (Nelson, H.S., 1997).
7. Dermatographism- is a skin condition also known as skin writing that causes the skin to
redden when lightly scratched and develop a raised wheal similar to hives.
8. False Positive Result- Operator presses the instrument too hard against the skin, causing
erythema from technique versus true allergic response to antigen, causing a false positive
SPT result (Carr, W. et al., 2005).
9. False Negative Result- Operator may not press the SPT instrument hard enough against
the skin so the antigen cannot penetrate the epidermis, resulting in a false negative SPT
result.
10. Skin Prick Test Sites Marking- Sites should be marked with washable blue markers to
identify placement of solutions and pricks should be made immediately adjacent to the
marks to avoid confusion between solutions.
Research Methods and Procedures
Description of Research Design
This Doctor of Nursing Capstone Research Project was a prospective, double-blind
clinical trial using a convenience sample in which pediatric research participants underwent SPT
in a single session, with a single operator using the Duotip twist and Quintip puncture techniques
as compared to the Duotip prick/lift technique. Each device was tested on the back and included
two histamine solutions (10 mg/mL; Hollister-Stier, Spokane, Wash) and two glycerol-saline
solutions (Hollister-Stier), in a vertical column and spaced at least 3 cm apart.
To maintain objectivity, the operator who performed the SPT on the back, was blinded to
the contents of the test solutions of histamine or saline (Carr et al., 2005). An additional operator,
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who was not present in the room during solution placement and SPT procedure, recorded the
results at 15 minutes post procedure. This operator was blinded to the device used at each test
site, as well as the specific solution tested on the back of each pediatric research participant.
All SPT were performed using histamine solutions (10 mg/mL; Hollister-Stier, Spokane,
Washington) as the positive solution and glycerol-saline solutions (Hollister-Stier) as the
negative control to compare variability of the SPT size.
Identification of the Population and Sample Selection
All patients followed at the study site, who met the entry criteria, were offered enrollment
into this study. It was estimated that 50 patients were seen weekly, requiring the SPT procedure
as a part of their clinical treatment activities. Of the known patients, approximately 20 eligible
patients were identified each week.
The small population of 600 children was seen at the facility during the study enrollment
period. A total sample size of 68 pediatric research participants was enrolled into this study.
Each participant received 12 SPT on his or her back body surface, which were used to determine
variability and reproducibility of the three techniques. Research participant served as his or her
own control and were tested using a blinded tray filled with two histamine and two saline
solutions for each technique and device used by a single trained operator.
Power analysis to determine sample size. A sample size of 68 pediatric research
participants was calculated to achieve a 95% power or sensitivity to detect differences in
standard deviation between the two devices and three techniques (Faino, 2013).
Parameters that went into calculation included:


Alpha= 0.05



Standard Deviation (Quintip, back)= 0.95
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Standard Deviation (Greer Pick, back) = 1.81 (Values from Werther et al., 2012)

Note: Greer Pick is a surrogate to Duotip twist
N1 verses Power S1 = 1.8100, S2 = 0.9500, Alpha = 0.05, N2 = N1, 2-sided F Test
Table 2. Power Analysis of Variances

Power analysis of variances. Numeric: Results when H0: S1 = S2 verses Ha: S1 ≠ S2
Power

N1

N2

S1

S2

Alpha

Beta

0.990636
0.953888
0.907893
0.856790
0.803054
0.758083
0.704637

47
34
28
24
21
19
17

47
34
28
24
21
19
17

1.8100
1.8100
1.8100
1.8100
1.8100
1.8100
1.8100

0.9500
0.9500
0.9500
0.9500
0.9500
0.9500
0.9500

0.050000
0.050000
0.050000
0.050000
0.050000
0.050000
0.050000

0.009364
0.046112
0.092107
0.143210
0.196946
0.241917
0.295363

*This test was assuming independence between the groups and was likely an overestimation
of the total number of patients needed. Thus additional participants were not needed to cover for
unusable data (Faino, 2013).
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Population/sampling parameters. All current and newly diagnosed patients (based on
medical history and/or community physicians referral information) with suspected food, drug or
environmental allergies, were offered enrollment into this DNP Capstone Research Project.
The Inclusion Criteria:
1. Children with suspected food, drug, or environmental allergies - ages 1 to 16 years old
2. Both genders, all races and ethnic groups
3. English speaking only
4. Medications, included but not limited to antihistamines, withheld for appropriate time
period as per hospital protocol
The Exclusion Criteria:
1. Inability to comply with SPT procedure
2. Failure of a family/patient to sign the informed consent document or the HIPAA medical
record release form
Recruitment plan. In order to maximize recruitment of participants with suspected food,
drug, or environmental allergies, two recruitment strategies were used:
1. Current and future Clinical Site Patients - The principal investigator discussed the study
design, benefits and possible risks with the family. Printed information about the study
and the consent form were given to the family. The IRB-approved consent form included
the purpose of the trial, the responsible parties and investigator, potential benefits, risks
of participation, the right to refuse to be in the study, the right to withdraw from the study
under no penalty, contact numbers and information about the responsibility for injury and
payment for medical care. If the family consented to participant in the study, written
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informed consent was obtained from the parents or guardians and case report forms were
completed.
2. Advertising Strategy for Voluntary Enrollment- To increase the sample size, several steps
were taken to add to the recruitment of study participants. A periodic IRB-approved
announcement of the objectives of the DNP Capstone Research Project was made on the
Pediatric Department Bulletin Board with a request for referral of patients. In addition,
the principal investigator posted IRB approved notices on the Pediatric Clinic and
Pediatric Care Unit bulletin boards to announce the new study and provided contact
information for interested families or patients.
Study enrollment. During the six-month duration of this study, the plan was to enroll 68
patients at the study site. The ethnicity and racial categories of the participants are outlined in
Table 3.
Table 3. Planned Enrollment Table.
Ethnic Categories

Hispanic or Latino
Not Hispanic or Latino
Ethnic Categories: Total of All
Participants
Racial Categories
American Indian/Alaska Native
Asian
Native Hawaiian or Other Pacific
Islander
Black or African American
White
Racial Categories: Total of All
Participants

Gender
Females
6
27
33

Males
7
28
35

Total
13
55
68

1
1
0

1
1
0

2
2
0

3
28
33

4
29
35

7
68

19

Setting Description
Participants were recruited from patients evaluated, referred, and followed at the study
site in Denver, Colorado. The principal investigator identified the parent(s) or guardian(s)
during Pediatric Clinic visits or during inpatient, day patient admissions, or triage visits within
the Pediatric Care Unit. The principal investigator discussed the study design, benefits and
possible risks with the family. Printed information about the study and a copy of the consent
form were given to the family.
Stakeholders and Project Team
Mentor. Dr. Erwin Gelfand, Chairman Department of Pediatrics, provided mentorship
and guidance to the author and principal investigator of this DNP Capstone Research Project. Dr.
Gelfand is internationally recognized as reporting of his research endeavors, publications and
leadership positions posted on the facility website (http://www.nationaljewish.org/about/peoplesearch, 2013).
Capstone Chair. Dr. Diane Ernst, Associate Professor at Regis University, provided
education and guidance throughout this DNP Capstone Research Project. Dr. Ernst's clinical
expertise and certification are centered on community and public health outcomes. Her research
activities include nursing-sensitive outcomes research, health promotion and illness prevention
in older adults, and research within the community/public health settings.
Medical Director at the study site. Dr. Pia Hauk, Medical Director Department of
Pediatrics, provided medical assistance as necessary if an adverse event occurred. Dr. Hauk
oversees all clinical activities within the Department of Pediatrics including the areas of the
Pediatric Clinic, Triage, and Pediatric Care Unit.
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Additional advisory team members. To complete the DNP Capstone Research Project,
active collaboration occurred with Anna Faino, Biostatistician at the facility. Following the
departure of Ms. Faino from the institution, Dr. Ronina Covar, Associate Professor in the
Division of Pediatric Allergy and Clinical Immunology and Director of The Cohen Family
Asthma Institute, Head of Pediatric Clinical Pharmacology, and Biostatistician assisted in the
statistical validation and analysis of the study. Pediatric Physician Specialists from the facility,
whom raised the initial concerns regarding concern of operator variability, were available during
the enrollment period. Ms. Kelly Buller, RN and SPT preceptor, and Ms. Suseth Figueroa, expert
SPT operator, were regularly consulted regarding SPT technique, education, and training.
The facility's mission, vision, and organizational structure supported the educational
endeavor and provided the necessary physical and financial support to complete the project. Dr.
Erwin Gelfand and other members of the advisory team are experts in their field and provided
necessary guidance to the overall success of the project.
Community partnerships. In order for this project to be successful, community efforts
from different teams were developed. For example, the DNP Capstone Research Project involved
two separate device manufacturers and the Institutional Review Boards at Regis University and
the study site. The two Institutional Review Boards worked together to ensure the safety of
research participants and allowed medical research to proceed in an ethical manner without
either intentional or unintentional abuses of power or errors
Interdisciplinary collaboration. Conducting research to identify a single SPT device
and technique required interdisciplinary collaboration. Adult and pediatric health care teams
relied on accurate results to define initial diagnoses and ongoing treatment plans for allergic
patients. Support staff and SPT operators were able to identify appropriate patients for the

21
project. The principal investigator collaborated fully with the attending physicians to approach
potential patients for participation. At the conclusion of the study, results were shared with all
departments and policy and procedure were amended to reflect the superior device and
technique. Communication was extensive with all health care team members at the table for
discussion of results.
Protection of Human Rights Procedures
Institutional review boards. The research protocol, consent, assent, and other regulatory
documents were reviewed and approved by the facility's Institutional Review Board and Regis
University Institutional Review Board. All pediatric research participants enrolled into the study
voluntarily agreed to participate and gave written informed consent by parent or legal guardian
and assent from child research participant.
Regis University institutional review board. verified and approved all research
activities involving human research. The board met monthly to verify exempt studies, determine
and review expedited studies, and conduct formal meetings for studies requiring full review.
Even though this study involved a vulnerable population, the research was minimal risk and
qualified for expedited review. Two designated Regis University IRB members reviewed the
regulatory packet and granted approval.
Facility's institutional review board. was consulted during the development of the
DNP Capstone Research Project and determined that the protocol met the requirements for
expedited review.
As described on the facility's website (2013), "Expedited review is an option when
the research activity will expose participants to no more than minimal risk and when the
proposed study falls into a category described in the federal regulations. Because the risks of
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participating in the research are no more than minimal, the regulations allow the study to be
reviewed by the IRB Chairperson or an experienced IRB member".
Procedure for requesting an expedited review of a new protocol. Author and
principal investigator applied for expedited review and completed the appropriate submission
requirements found on their website There were no submission deadlines for expedited
review. Once the regulatory packet was logged into the system, a Primary Reviewer was
assigned to the protocol and communicated directly with the principal investigator or IRB
contact person. Once all stipulations had been adequately addressed, the protocol was
approved and the principal investigator was notified. An expedited review required two to
three weeks, but it is dependent upon the availability of the Primary Reviewer.
Informed consent plan. All potential participants were identified by the principal
investigator and those meeting the inclusion/exclusion criteria were given the opportunity to
participate. Parents/guardians/ participants were given the consent/assent forms to review and
ask questions about the study. Parents/guardians/participants were asked to summarize in
their own words what participation in this research study involved and that they are
comfortable with the risks and benefits of participating in the research study. Any additional
questions they had were answered prior to signing the consent/assent. Once the
consent/assent form was signed, a copy was provided to the parent/guardian/participant. All
participants were consented by the Principal Investigator who had appropriate training
regarding human participant protection and HIPAA compliance, as established by the local
institutional regulatory requirements. Only English speaking participants were able to
participate in the study.
Special consent/assent plan. Spanish only speaking population were excluded from
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this study. Children 7 years of age and greater were asked to sign assent after the protocol
was explained by the principal investigator.
Incentives or rewards offered for participation. Patients, parents or guardians did not
receive reimbursement for their participation in this research study. Patients were not charged for
their participation in this study.
Potential risks to participants. There were minimal physical and psychological risks
from being in this study. Brief minimal localized site pain was associated with the SPT
procedure and resolved immediately without treatment once the prick was completed. No
additional treatment was necessary to resolve pain.
Alternative treatments considered. Patients could have elected to not participate in the
study and receive SPT as a part of their routine clinical care.
Plan to protect participants/mitigate risks. The study anticipated no excessive risks to
the patients, except the possible pain associated with the SPT. Once the procedure was
completed and in the 15-minute wait period, a small fan was directed to the back area to
minimize any discomfort if requested.
Criteria for removal from study. Participants were seen one time immediately
following enrollment into the study. The participants' parents or guardians could request that the
patient be removed from the study at any time. In addition, the investigator could withdraw a
participant from the study if she determined that it was in the participant’s best interests.
Withdrawal from the study would not impact the study participant’s future medical care.
Potential health benefits to participants. The pediatric research participants did not
directly benefit from participation in this research, but in the future, other children needing to
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undergo the SPT procedure may benefit from new information that may lead to better medical
care.
Importance of the knowledge gained from this research. was to better understand of
the SPT technique and devices used, and lead to improvements in diagnoses and treatments for
food, drug and environmental allergies. This study was designed to identify a single device and
technique that could be used at the facility to reduce variability, increase reliability, and
standardize the procedure using a single technique and device within the institution.
Description of the Study Intervention/ Protocol
This prospective, double-blind research study offered comparison in the performance of
the Duotip twist and Quintip puncture techniques as compared to the Duotip prick/lift technique.
The purpose of this study was to determine the best SPT technique and device that could be used
efficiently and effectively to identify and treat severe allergies to drugs, foods and environmental
allergens. This inexpensive test has the potential to yield enormous results at a single visit and
dictate lifesaving treatment, which is patient specific.
This DNP Clinical Research Project was performed under Good Clinical Practice
guidelines (FDA, 2013), which enforced tight rules on ethical aspects for human research. Good
Clinical Practice guidelines aim to ensure that studies are scientifically valid, necessary
procedure and tests are safely performed, and all research activities are accurately documented.
In addition, the Good Clinical Practice Guidelines provide information about subject protection,
roles and responsibilities of the research team and participants, and study oversight (FDA, 2013).
Four Certified Nursing Assistants and two Registered Nurses involved in this DNP Clinical
Research Project completed their CITI training and other regulatory requirements as required by
the local Institutional Review Board. Medical liaisons from Lincoln Diagnostics, Inc. and
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Hollister Stier, manufacturers of the devices, provided educational training sessions on the
Quintip punch technique and the Duotip twist technique before first subject was enrolled into the
study. Operators performed all SPT on the pediatric research participants, and another trained
SPT operator immediately read all of the results at a specific time interval and documented the
results in the SPT test form.
Research intervention. Each subject underwent 12 SPT during a single session with a
single operator using the Duotip twist and Quintip puncture techniques as compared to the
Duotip prick/lift technique. Each technique and device were tested on the back of the pediatric
participant, using two tests of the histamine (10 mg/mL; Hollister-Stier, Spokane, Wash) positive
control solutions and two tests of the glycerol-saline (Hollister-Stier) negative control solutions
during the session. At the conclusion, a mean result was determined for each test of the single
use devices, and from this, intradevice variability was defined. Single device test sites were
spaced at least 3 cm apart, in three row of four SPT, and marked with a pen on the back to
properly identify test locations.
To maintain objectivity, the operators who performed the SPT on the back were blinded
to the contents of the test solution of histamine or saline control solutions. An additional
operator, who were not be present in the room during application and testing of solutions and
controls, recorded the results. This operator was blinded to the devices used as well as to the
particular solution placements on the back of the research participant. The largest diameter was
measured first using a clear ruler, followed by the perpendicular diameter, passing through the
middle of the wheal and documented. The measurement was repeated on the surrounding
erythema or flare response using the same technique. Wheals greater than 3 mm in diameter were
considered positive at the histamine sites and indicative of clinical allergic response.

26
Discussion of Measurement Techniques/ Instruments
Devices. Single headed devices were evaluated in the DNP Capstone Research Project
including the Duotip (Lincoln Diagnostics) used for the prick and twist techniques and the
Quintip (Hollister-Stier) used for the punch technique.
Skin prick testing. All testing was performed on the back. The wheal and flare results
were recorded at 15 minutes post placement by obtaining the longest orthogonal diameters. Mean
diameters were used for statistical analyses. Positive test solution was 10-mg/mL histamine
(Hollister-Stier), with standard glycerol saline (Hollister-Stier) used as the negative solution. The
controls were tested twice in each row to ensure reactivity and variability for each device. The
different SPT studied in this protocol share clinical responsibilities for the diagnosis and
treatment of pediatric allergies. In the following, the current state of knowledge about each
technique was summarized and current scientific and clinical challenges were outlined.
1. Duotip prick and twist techniques- Lincoln Diagnostics. Duotip-Test® is the most
affordable one-at-a-time SPT on the market (www.lincolndiagnostics.com, 2013).
As reported on the Lincoln Diagnostic website (2013), the Duotip is:


Highly sensitive and specific



Well-defined, easy-to-read reactions



Excellent patient acceptance



Rapid, convenient, and easily learned technique as reported by manufacturer



Used via modified prick or rotation (twist)



Lowest cost one-at-a-time procedure per manufacturer report



Compact system requires little storage and disposal space



OSHA Compliant for blood borne pathogens and needle stick prevention
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2. Quintip punch technique- Hollister-Stier. Quintip is a SPT device manufactured by
Hollister-Stier Laboratories, Spokane Washington. The Quintip is designed to perform as
reported on their website (http://www.hsallergy.com):


to apply allergen extract using a puncture technique



Stainless steel lancet tip that protrudes from the molded plastic grip, enough to give the
proper testing grip



Is to be used once and discarded in appropriate sharp container



Can be stored in the extract-filled trays when not in use or in shipping package



With the Quintip perpendicular to the skin, tester presses down on the skin with medium
pressure without lifting the device from the skin. Remove by lifting vertically and discard
in approved sharps container. A small visible circle should remain at the test site
indicating that the correct amount of pressure was applied



The visibility of the circles will vary between patients according to thickness, fragility,
and pigmentation of the patient's skin

Plan for Data Collection
Data collection and study visit schedule. This study involved collection of clinical
information, medical history, medication history, brief physical findings, and SPT.
The following data was collected on study participants at enrollment and during the single study
visit.
Enrollment/Study Visit 1
1. Demographics: age at entry, date of birth, gender, race and ethnicity
2. Clinical Presentation: brief history of allergic symptoms, signs, age at onset, and initial
interventions
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3. Current Medications and Diet History
4. Brief Physical examination: Measurements: vital signs; Appearance: skin assessment
5. Skin Prick Tests: using Duotip prick and twist technique and Quintip punch technique
Table 4. Study Visit
The single study visit included the following:
EVALUATION

VISIT 1

Informed Consent

X

Eligibility

X

Medical History

X

Medication History

X

Brief Physical Examination

X

Skin Prick Tests

X

Discharge

X

Plan for Data/ Statistical Analysis
Wheal results were analyzed using repeated-measures ANOVA (Analysis of Variance)
with the limited factors of back body site of 68 pediatric research participants and device. When
calculating sensitivity and specificity, a positive test had a wheal of 3 mm or greater, and the
negative test had a wheal of less than 3 mm. If the histamine results were less than 3 mm, the
result was considered a false negative. Wheals greater than 3 mm in diameter were considered
positive and indicative of clinical allergic response.
Skin prick test results were recorded using the largest diameter (D1) measured first using
a clear ruler, followed by the perpendicular diameter (D2), and passing through the middle of the
wheal. The measurement was repeated on the surrounding erythema or flare response using the
same technique. The mean diameter (MD) was calculated using the formula:
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MD = (D1 + D2)/2.
Sensitivity of each technique was calculated using the true positive result of 3 mm for the
mean diameter (MD) of each wheal. Similar to the analyses of Masse et al. (2011) research study
and Carr et al., (2005) research study, sensitivity was calculated by dividing true positive results
by the sum of true positive and false negative results. Specificity of each technique was
calculated by using the true negative results divided by the sum of the true negative and false
positive results. The positive predictive value (PPV) is the proportion of subjects that are actually
positive, among those that are predicted to be positive. The negative predictive value (NPV) is
the proportion of subjects that are actually non-positive, among those that are predicted to be
non-positive, and was calculated using the formula.
Interpatient reproducibility (using the same technique on multiple patients) and
intrapatient reproducibility (same patient but using different techniques) were researched in this
study. To assess intrapatient (same patient) reproducibility, the coefficient of variation (CV)
between the mean diameters (MD) of the results using the same technique were calculated using
the following formula (Masse et al., 2011):
CV intrapatient = SD intrapatient / μ intrapatient
where the SD and μ are the standard deviation and the MD of the results.
Interpatient (different patient, same technique) variation of wheal size comparing
different patients using same technique were calculated using the following formula (Masse et
al., 2011):
CV interpatient = SD interpatient / μ interpatient
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The coefficient of variation represented the ratio of the standard deviation to the mean and was
an essential statistical measurement used to compare the degrees of variation from one device
and technique to another regardless how different the means were to one another.
The formal statistical method to measure the variability in wheal size for each of the three
techniques was performed using a single multilevel model. As noted by Werther et al., (2012),
this allowed for "correlations between observations taken by the same operator and carried out
on the same receiver using random effects". The model separated the variability in SPT
measurements into 3 components: variability between operators, variability between receivers,
and variability within operators and receivers".
With the assistance from the Dr. Ronina Covar at the facility, sensitivity and specificity
were calculated and variation defined between SPT techniques and devices.
Results
Study hypotheses. The following hypotheses were tested in this study:
1. Each of the three SPT techniques- Quintip device puncture technique, Duotip device
twist technique, and the Duotip prick technique- produce a positive wheal > 3mm to the
positive control of histamine on the back of the pediatric research participant.
2. Variability in SPT results was greatest using the Duotip prick technique among multiple
operators.
3. Variability in SPT results was the least using the Quintip device puncture technique,
regardless of operator change.
4. The Quintip puncture technique was highly reproducible as compared to the Duotip prick
and twist techniques.
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A total of 68 children with a mean age of nine years (range: 4-16 years) participated in
the study (Figure 1). Thirty-nine males and 29 females enrolled with their specific race and
ethnicity demographics defined in Figure 2 and Figure 3.

Figure 1. Age of subjects at time of enrollment
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Indian, NonHispanic Male
3%

Total Males Enrolled
Black, Hispanic,
Male
8%

Black, NonHispanic, Male
10%

Caucasian, NonHispanic, Male
38%
Caucasian,
Hispanic, Male
41%

Figure 2. Race and ethnicity results of males enrolled

Total Females Enrolled
Indian, NonHispanic Female
3%

Black, Hispanic,
Female
7%
Black, NonHispanic, Female
4%

Caucasian, NonHispanic, Female
45%

Caucasian,
Hispanic,
Female
41%

Figure 3. Race and ethnicity results of females enrolled
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Study Hypothesis #1: Each of the three SPT techniques- Quintip device puncture
technique, Duotip device twist technique, and the Duotip prick technique- produce a
positive wheal > 3mm to the positive control of histamine on the back of the pediatric
research participant.
Results revealed that each of the three SPT techniques- Quintip device puncture
technique, Duotip device twist technique, and the Duotip prick technique- produced positive
wheals > 3mm to the positive control of histamine on the back of the pediatric research
participants, supporting the research hypothesis (Table 5).
Each subject had at least one True Positive (TP) wheal defined as > 3 mm in mean
diameter and one True Negative (TN) wheal < 3mm in mean diameter.
Each of the three SPT techniques- Quintip device puncture technique, Duotip device
twist technique, and the Duotip prick technique- produce a positive wheal > 3mm.
Table 5. Median Wheal Size
Technique

Minimum

10%

25%

Median

75%

90%

Maximum

Prick/Lift

0

2.35

4

5

6.5

7.5

12

Punch

0

2

4

5

5

6.5

8

Twist

0

4

5

6.5

7.5

8.5

14.5

Using a non-parametric statistical method, Wilcoxon test, to rank each test in numerical
order against each test and then against each technique using the median value in 4 different
quartiles, the analysis revealed that all three techniques produced positive wheals when exposed
to the positive antigen of histamine. Each subject had at least one True Positive (TP) wheal
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defined as > 3 mm in mean diameter and one True Negative (TN) wheal < 3mm in mean
diameter.
Mean diameter of wheals, small red bumps developed on the skin where the allergens
were placed, were recorded at precisely 15 minutes later by a second trained operator. For this
study, the size of the wheals only represented positive skin prick tests and did not indicate the
severity of the symptoms or sensitivity to the histamine (true positive) or saline (false positive).
Table 6. Sensitivity and Specificity
Technique/device

TP

FN

Sensitivity %

Specificity %

Quintip Punch

117

19

86%

96.3%

Duotip Prick/Lift

121

15

88.9%

97%

Duotip Twist

132

4

97%

83.8%

Comparing results between the three techniques and two devices, the twist method was
most sensitive (97%) as compared to the punch technique (86%) and prick/lift technique (89%).
Only 2.8% of those tested using the twist technique produced false negative responses to
histamine as compared to 14% (Quintip punch) and 11.1% (Duotip prick/lift).
The SPT with 100% sensitivity correctly identifies all subjects with the positive
histamine response. The overall SPT sensitivity detected 91% of subjects with a true positive
response to histamine and a 9% of false negative responses to histamine (false negative).
Sensitivity is paramount when the SPT is used to make treatment decisions, open diets, and
allow exposure to allergens.
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Table 7. Contingency Analysis of Positive (H) vs. Negative (S)
Technique

Test

ChiSquare

Prob>ChiSquare

PrickLift

Pearson

202.634

<.0001

Punch

Pearson

186.446

<.0001

Twist

Pearson

181.114

<.0001

Technique

FN

FP

TN

TP

PrickLift

15

4

132

121

Punch

19

5

131

117

Twist

4

22

114

132

Number

Test

ChiSquare

Prob>ChiSquare

816

Pearson

31.940

<.0001

Measures of Association- Pearson Test ChiSquare was used for this study as defined in
Table 7. Since the rows and columns in a table were completely independent of each other, the
entries in the table (distribution of mass) were reproduced from the row and column totals alone,
or row and column comparison analysis. The sums of the frequencies across the columns must be
equal to the row totals, and the sums across the rows equal to the column totals. The results for
this DNP study were found to be statistically significant as represented by the p value <.0001.
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Study Hypothesis #2: Variability in SPT results was greatest using the Duotip prick
technique among multiple operators.
Variability in the SPT results to histamine was greatest using the Duotip prick technique
among multiple operators.
Table 8. Variability in SPT to Histamine
HISTAMINE
Technique/Device

Number

Mean

Standard
Deviation

Co-efficient
of Variation

Prick/Lift

136

4.95221

2.17722

44.0

Punch

136

4.35662

1.74686

40.1

Twist

136

6.46750

2.36714

36.6

The one-way AVONA analysis using parametric measurements and a p value of less than
0.0001 suggested that the Duotip prick lift method was highest as compared to the other methods
as defined by the Co-efficient of Variation, or the variation in the ability to repeat the test in
same tests in patients.
Duotip twist method was highly sensitive as noted on the previous slide (97%) even
though the mean (6.5) and standard deviation are largest (2.36714). Results indicate the twist
tests are highly reproducible as noted with the lowest coefficient of variation (36.6).
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Study Hypothesis #3: Variability in SPT results was the least using the Quintip
device puncture technique, regardless of operator change.
Variability in the SPT results to histamine was least using the Duotip twist technique
among multiple operators (Table 9).
Table 9. Variability in SPT- Mean, Median, and CV
HISTAMINE
Technique/Device

Median

Mean

Prick/Lift

5.0 (4.0, 6.5)

5.0±2.2

Co-efficient
of Variation
44.0

Punch

5.0 (4.0, 5.0)

4.4±1.7

40.1

Twist

6.5 (5.0, 7.5)

6.5±2.4

36.6

Variability in SPT results was the least using the Quintip device puncture technique,
regardless of operator change.
Using the Wilcoxon test to conduct non-parametric analysis using the median data and
ANOVA test to conduct parametric analysis using the mean data, resulted in the same message
that the twist method using the Duotip device had the least variation in results.
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Research Hypothesis #4: The Quintip puncture technique was highly reproducible
as compared to the Duotip prick and twist techniques.
Table 10. Reproducibility of Techniques
HISTAMINE
Technique/
Device
Prick/Lift

Median

Mean

5.0 (4.0, 6.5) 5.0±2.

Punch
Twist

CV

TP

FN

Sensitivity

Specificity

44.0

121

15

89%

97%

5.0 (4.0, 5.0) 4.4±1.

40.1

117

19

86%

97%

6.5 (5.0, 7.5) 6.5±2.

36.6

132

4

97%

84%

The Quintip puncture technique was highly reproducible as compared to the Duotip prick
and twist techniques as defined by the differences in wheal means and standard deviations of the
data between the different techniques. The one-way AVONA analysis using parametric
measurements and a p value of less than 0.0001 further suggested that the Duotip twist method
was highly sensitive and able to provide true positive results while limiting false negative SPT
results when conducted on the back of children.
The Coefficient of variation, or the variation in the ability to repeat the same test in
patient, is the lowest with the twist, using histamine and saline, as compared to the other two
techniques (Table 10).
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Table 11. Mean Wheal Diameter

The median wheal diameter is largest with the twist (6.5) as compared to the prick/lift
and punch (5). In addition the twist has the largest histamine wheal (14.5) when compared to the
prick/lift (12) and punch (8). This may be reflective of the “twisting” or traumatic nature of the
technique.
Another way to look at the data included comparing the two histamines within a given
column and comparing the overall pairs to one another. The statistical differences in matched
pairs within columns were identified and compared to all matched pairs in total to identify the
mean differences. The Prick Lift had the greatest mean difference in histamine measurements
between H1 and H2 as reflected by the P value of 0.0387.
The twist technique was the least variable and most reproducible with the mean
difference of -0.082 between H1 and H2.
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Table 12. Agreement between H1 and H2
Agreement between H1 and H2 using continuous variables
Technique

Test

Result

PrickLift

H2

5.213

PrickLift

H1

4.691

Prick Lift

Mean Difference

0.522

Punch

H2

4.125

Punch

H1

4.588

Punch

Mean Difference

-0.463

Twist

H2

6.426

Twist

H1

6.508

Twist

Mean Difference

-0.082

Statistical Significance

0.0387

0.0878

0.7937

In conclusion, with proper education and training the skin prick test can be used to
identify and treat severe allergies to drugs, foods and environmental allergens. This inexpensive
test has the potential the yield enormous results at a single visit and dictate life saving treatment,
which is patient specific. This prospective, head-to-head comparison of the performance of two
single use skin test devices using the Duotip twist method and Quintip punch method as
compared to the Duotip prick/lift method. This study was performed under the best of clinical
circumstances, with operators trained by representatives of the manufacturers, and who
performed all skin testing, and another trained skin test operator who read all of the results. We
found significant differences among all devices to be tested.
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Dissemination of Study Results
Data results were shared once all research participants were enrolled, study visits
complete and data analyzed. Information was shared internally at the Pediatric Faculty meeting
and staff meetings within the Pediatric Care Unit and Pediatric Clinic in the study site.
Implication for Practice and Future Research
Interestingly, even though SPT is associated with minimal pain and yielding significant,
very little research has occurred to verify its reliability or define clinical treatment protocols for
its use. As new devices and techniques are being produced, continued evaluation of these devices
will be to be conducted to determine potential for variability and reproducibility among SPT
operators across all age groups.
Following the outcome of this DNP Capstone Research Project, future research
investigations may include:
•

Food, Environmental, and Medication allergen testing on pediatric patients

•

RAST results correlated to SPT results

•

SPT results correlated to Oral Food Challenges

•

New devices and techniques compared to the outcome of this study

Recommendations for on-going skin prick testing. Skin prick testing research must be
continual and new devices must be assessed before implementation regardless of the age group
for intended use. With proper education and training, the skin prick test can be used to identify
and treat severe allergies to drugs, foods and environmental allergens. Overall, skin testing is
associated with minimal pain, and individual physicians commonly use the test to diagnose and
treat drug, food and environmental allergies. As new devices and techniques are being produced,
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continued evaluation of these devices will be to be conducted to determine potential for
variability and reproducibility among skin test operators.
In summary, this Doctor of Nursing Practice (DNP) Clinical Research Project aimed to
discover knowledge of skin prick test (SPT) technique to enhance diagnosis and treatment of
potentially life threatening allergies in the pediatric population at National Jewish Health's
NJ4Kids Program. The results will integrate research, clinical and educational efforts to
positively impact clinical care through evidence-based research in the pediatric population.
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Timeframe and Budget/ Resources
Table 13. Logic Model for the Doctor of Nursing Practice Clinical Research Project
ResourcesInput

Activities

Constraints Outputs

Outcomes

Impacts

Funding in
the form of
supplies
supporting
Capstone
Research
Project

Provide
immediate
SPT results
for allergen
testing

Devices and Deliver
allergens are prompt
eliminated
diagnostic
results for
food, drug,
and
environmental
allergens

Early and
immediate
diagnosis of
allergic
triggers

Comprehens
ive grant
management of
clinical
research
study
including
regulatory
and clinical
research
activities.
The facility
Outpatient,
Infrastructure laboratory
and
Pediatric
Care Unit
facilities

Delay in
IRB
approval

Adherence to
grant policy
and
procedures as
mandated by
local internal
review board.

Regulatory
oversight for
Participant
and Principal
Investigator

Project
funded with
supplies
through
August
2014
(revised
December
2014)
First clinical
research
study
submitted to
IRBDecember
2013
(Revised
March
2014)

Potential
lack of
clinical
space due to
busy daily
clinics

Attend
scheduled
research visit

Immediate
access to the
facility for
validation of
initial
diagnosis

Allergist
unavailable

Research and
Grant
infrastructure
of the facility

Early
intervention
with
laboratory
and clinical
diagnostic
evaluations

Increased
patient
satisfaction
by providing
comprehensi
ve care in
clinic
Validation of Results
initial positive evaluated
SP
immediately
and plan
discussed
with patient

Adequate
space and
support

Early
intervention
and
treatment
for
identified
allergies

44
Study Timeline
Planned duration of the entire study. It was anticipated that enrollment would begin in
March 2014 and conclude within two months. Data was analyzed and prepared for submission
for publication in Winter 2014.


CITI Training for SPT Operators- December 2013



Regis DNP Proposal Presentation- March 2015



IRB submission to the facility's Institutional Review Board- March 2014



IRB submission to Regis University Review Boards- May 2014



Medical Liaison Training Presentations- January 2014



Research Protocol Presentation to the facility Faculty and Staff- June 2014



Enrollment Period- August-October 2014



Data Analysis- November-2014 -August 2015



Final Presentation- September 2015
Duration of participation for each participant. Each research participant’s

involvement in this research study occurred on a single day with the study visit lasting less than
two hours. This included the informed consent discussion and SPT procedure.
Study Budget/ Resources
In 2012, the State of Colorado elected to not reimburse for the SPT and instead would
only provide financial coverage for oral food challenges. Specialists from the facility and other
allergy practices pleaded with the State Health Department and state lawmakers to reconsider,
arguing the oral food challenges place the patients at extreme risk that are unknown beforehand
if SPT is not performed ahead of time. The State of Colorado reversed their decision and now
reimburse for the tests (Gelfand, 2013). Most private insurance companies and health
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maintenance organizations pay for this service and prefer to limit oral food challenges until
deemed safe to do so.

46
References
American Academy of Allergy, Asthma and Immunology (AAAAI) (2013). Skin prick testing.
Retrieved from http://www.aaaai.org/conditions-and-treatments/library/at-a-glance/allergytesting.aspx.
American Psychological Association. (2010). Publication Manual of the American
Psychological Association (6th ed.). Washington, DC: Author.
Atkins, F. M., Steinberg, S. S., & Metcalfe, D. D. (1985). Evaluation of immediate adverse
reactions to foods in adult patients: I. Correlation of demographic, laboratory, and prick skin
test data with response to controlled oral food challenge. Journal of Allergy and Clinical
Immunology, 75(3), 348-355.
Bernstein, I. L., Li, J. T., Bernstein, D. I., Hamilton, R., Spector, S. L., Tan, R., ... & Weber, R.
(2008). Allergy diagnostic testing: an updated practice parameter. Annals of Allergy, Asthma
& Immunology, 100(3), S1-S148.
Blackley, C. H. (1873). Experimental Researches on the Causes and Nature of Catarrhus
Aestivus (Hay-Fever or Hay-Asthma). Retrieved from
http://www.archive.org/stream/experimentalres00blacgoog#page/n4/mode/2up.
Carr, W. W., Martin, B., Howard, R. S., Cox, L., & Borish, L. (2005). Comparison of test
devices for skin prick testing. Journal of Allergy and Clinical Immunology, 116(2), 341-346.
Carr, T. F., & Saltoun, C. A. (2012, May). Skin testing in allergy. Allergy and Asthma
Proceedings 33(3), S6-S8.
Chafen, J. J. S., Newberry, S. J., Riedl, M. A., Bravata, D. M., Maglione, M., Suttorp, M. J., ... &
Shekelle, P. G. (2010). Diagnosing and managing common food allergies. JAMA: The Journal
of the American Medical Association, 303(18), 1848-1856.

47
Cox L, Williams B, Sicherer S, Oppenheimer J, Sher L, Hamilton R, Golden D; American
College of Allergy, Asthma and Immunology Test Task Force; American Academy of
Allergy, Asthma and Immunology Specific IgE Test Task Force (2008). Pearls and pitfalls of
allergy diagnostic testing: report from the American College of Allergy, Asthma and
Immunology/American Academy of Allergy, Asthma and Immunology Specific IgE Test
Task Force. Annals of Allergy, Asthma and Immunology, 101(6): 580–592.
Corder, W. T., Hogan, M. B., & Wilson, N. W. (1996). Comparison of two disposable plastic
skin test devices with the bifurcated needle for epicutaneous allergy testing. Annals of Allergy,
Asthma & Immunology, 77(3), 222-226.
Demoly, P., Bousquet, J., Manderscheid, J. C., Dreborg, S., Dhivert, H., & Michel, F. B. (1991).
Precision of skin prick and puncture tests with nine techniques. Journal of Allergy and
Clinical Immunology, 88(5), 758-762.
Eigenmann, P. A., & Sampson, H. A. (1998). Interpreting skin prick tests in the evaluation of
food allergy in children. Pediatric Allergy and Immunology, 9(4), 186-191.
European Academy of Allergy and Clinical Immunology. Allergy Skin Testing. Retrieved from
http://www.eaaci.org.
Faino, A. (2013). Statistical analysis. Retrieved on December 06, 2013.
Food and Drug Administration (2013). Biologics, Blood, and Vaccines. Retrieved from
http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/
Fitzpatrick, J., & Whall, A. (2005). Conceptual models for nursing: analysis and application.
Upper Saddle River, New Jersey: Pearson Prentice Hall.
George, J. B. (2011). Nursing theories: The base for professional nursing practice (6th ed.).
Boston, MA: Person.

48
Heinzerling, L., Frew, A. J., Bindslev‐ Jensen, C., Bonini, S., Bousquet, J., Bresciani, M., ... &
Zuberbier, T. (2005). Standard skin prick testing and sensitization to inhalant allergens across
Europe–a survey from the GA2LEN network*. Allergy, 60(10), 1287-1300.
Heinzerling, L., Mari, A., Bergmann, K. C., Bresciani, M., Burbach, G., Darsow, U., ... &
Lockey, R. (2013). The skin prick test–European standards. Clinical and Translational
Allergy, 3(1), 3.
Hollister-Stier Laboratories. Quintip device. Retrieved from
http://www.hsallergy.com/sites/www/Uploads/Files/Products/ProductInserts/385415-H05.pdf
Houser, J., & Oman, K. S. (2011). Evidence-based practice: An implementation guide for
healthcare organizations. Sudbury, MA: Jones and Bartlett.
Institute for Healthcare Improvement. (n.d.). Asthma-skin testing. Retrieved from
http://www.ihi.org/IHI/Topics/PatientSafety/Asthmas/Resources.htm
Jasovsky, D., Morrow, M., Clementi, P., & Hindle, P. (2010). Theories in action and how
nursingpractice changed. Nursing Science Quarterly, 23(1), 29-38.
Krau, S. D., McInnis, L. A., & Parsons, L. (2010). Allergy skin testing: what nurses need to
know. Critical Care Nursing Clinics of North America, 22(1), 75-82.
Lewin, K. (1947). Frontiers in group dynamics: concept, technique and reality in social science;
social equilibria and social change. Human relations, 1(4), 5-41.
Lincoln Diagnostics, Inc. Duotip device. Retrieved from
http://www.lincolndiagnostics.com/products/duotip-test.
Masse, M. S., Granger Vallée, A., Chiriac, A., Dhivert-Donnadieu, H., Bousquet, Rouanet, L.,
Bousquet, P. J., & Demoly, P. (2011). Comparison of five techniques of skin prick tests used
routinely in Europe. Allergy, 66(11), 1415-1419.

49
National Jewish Health (2013). Find a Doctor. Retrieved from
http://www.nationaljewish.org/about/people-search/detail/?id=112.
Nelson H.S., Knoetzer J., Bucher B. (1997). Effect of distance between sites and region of the
body on results of skin prick tests. Journal of Allergy and Clinical Immunology, 97(2): 596601.
Nelson, H. S., Lahr, J., Buchmeier, A., & McCormick, D. (1998). Evaluation of devices for skin
prick testing. Journal of Allergy and Clinical Immunology, 101(2), 3-6.
Nelson, H. S., Rosloniec, D. M., McCall, L. I., & Iklé, D. (1993). Comparative performance of
five commercial prick skin test devices. Journal of Allergy and Clinical Immunology, 92(5),
750-756.
Nibert, M. 2.5.1 Boyer's Model of Scholarship. Retrieved from
http://www.pcrest.com/PC/FGB/test/2_5_1.htm
NIH MedlinePlus.gov. How to control your seasonal allergies. Retrieved from
http://www.nlm.nih.gov/medlineplus/magazine/issues/spring13/articles/spring13pg22-23.html
Rancé, F., Abbal, M., & Lauwers-Cancès, V. (2002). Improved screening for peanut allergy by
the combined use of skin prick tests and specific IgE assays. Journal of Allergy and Clinical
Immunology, 109(6), 1027-1033.
Rhodius, R., Wickens, K., Cheng, S., & Crane, J. (2002). A comparison of two skin test
methodologies and allergens from two different manufacturers. Annals of Allergy, Asthma &
Immunology, 88(4), 374-379.
Rogers, E. M. (1995). Diffusion of Innovation (4th ed.). New York: The Free Press.
Stillwell, S., Fineout-Overholt, E., Melnyk, B., & Williamson, K. (2010). Evidence-Based
Practice, Step by Step: Asking the Clinical Question A Key Step in Evidence-Based Practice.

50
American Journal of Nursing, 110(3), 58-61.
Spergel, J. M., Andrews, T., Brown-Whitehorn, T. F., Beausoleil, J. L., & Liacouras, C. A.
(2005). Treatment of eosinophilic esophagitis with specific food elimination diet directed by a
combination of skin prick and patch tests. Annals of Allergy, Asthma & Immunology, 95(4),
336-343.
United States Joint Council of Allergy, Asthma and Immunology. Skin Prick Testing. Retrieved
from http://www.jcaai.org.
Werther, R. L., Choo, S., Lee, K. J., Poole, D., Allen, K. J., & Tang, M. L. (2012). Variability in
Skin Prick Test Results Performed by Multiple Operators Depends on the Device Used. World
Allergy Organization Journal, 5(12), 200-204.
Yoder-Wise, P. S. (2007). Leading and managing in nursing (4th ed.). Mosby: St. Louis, MO
Yoon, I. K., Martin, B. L., & Carr, W. W. (2006, November). A comparison of two singleheaded and two multi-headed allergen skin test devices. Allergy and Asthma, 27(6), 473-478.
Zaccagnini, M. E., & White, K. W. (2011). The DNP essentials: A new model for advanced
practice nursing. Sudbury, MA: Jones and Bartlett.

51
Appendix A
SWOT ANALYSIS

STRENGTHS
1. What are your strengths?
2. What do you do better than others?
3. What unique capabilities and
resources do you possess?
4. What do others perceive as your strengths?

• Small tertiary facility
• Specialty hospital focusing on
pulomonary, asthma and allergy, and
immunology medicine
• World reknown xpertise in several
specialty areas
• Main hospital and several offsite
clinics
• Local partnerships with adult
intensive care units
• No patient will be turned away
regrdless of financial status
• Significant research experiencebench and clinical
• Seen at the center of "last resort" by
patients and referring physicians
• Patients referred from around the
world

WEAKNESSES
1. What are your weaknesses?
2. What do your competitors do
better than you?
3. What can you improve given
current situation?
4. What to others perceive as
your weaknesses?
• Large institution
• Multiple divisions covering all
disciplines and facets to make the
organization work • Supportive of hospital-wide quality
improvement
• Expertise in multiple specialty
areas/world-renowned healthcare
providers
• Advanced technological
infrastructure- EMR
• Regional coverage through network
of care sites
• Regional partnerships with other
healthcare networks – broadened
market share
• Allow customers of all payer mixes
• Magnet designated
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OPPORTUNITIES
1. What trends or conditions may positively
impact you?
2. What opportunities are available to you?

• Letter of Intent signed
with SCL/St. Joseph's
Hospital as first step of
a Joint Operating
Agreement
• Funded research
activities
• Partnerships with local
and national respected
academic medical
facilities
• Department of
Medicine has continued
to attract highly sought
after physicians
• Development has had a
banner year despite the
national economic
struggles
• 48 hour appointments
within the department
of pediatrics has
increased business 1316%

THREATS
1. What trends or conditions may
negatively impact you?
2. What are your competitors doing
that may impact you?
3. Do you have solid financial
support?
4. What impact do your
weaknesses have on the threats
to you?
• Competitor growing extremely
fast
• Competitor's large workforce
make standard processes
difficult to sustain and
implement
• Competitor has extremely
recognizable brand and
excellent marketing efforts,
allowing for solid financial
support from community and
foundation
• Competitor seeking to see
every pediatric medical visit in
the Rocky Mountain regionHuge competition
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Appendix B
Study Budget

Full Study Title: Reducing Variability
Among Multiple Operators Using a
Single Technique and Device for Skin
Prick Testing in Children
Protocol Number: HS 2826
Principal Investigator: Elizabeth Esterl
RN, MS
Sponsor: PI Initiated. Unfunded
Coordinator: Elizabeth Esterl RN, MS
Date: February 01, 2014
Facility IRB and Administrative
Invoiced Fees
These fees are to be paid immediately
upon receipt of invoice.
Initial Review Fee (subject to change)
Consent - Spanish Translation Fee
$40.00 per page/ 8 pages total
These fees are subject to change
upon notification from the local IRB

waiver
submitted

IRB

$200.00

Translation

Nonnegotiable
Nonnegotiable

waived
Fixed
Direct
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Full Study Title: Reducing Variability Among Multiple Operators Using a Single Technique and
Protocol Number: HS 2826
Principal Investigator: Elizabeth
Esterl RN, MS
Sponsor: PI Initiated. Unfunded
This is a 12 month budget and
pricing wil be increase 7% each year
thereafter based on the date of the
contract.
[ ] Budget accepted with NonRefundable Start up Fees and
Alacarte Menu of Fee for Services
Non-Refundable Start up Fees:
Protocol Development- Principal
Investigator
Protocol Review- Medical Director
Site Evaluation
IRB/Regulatory Document Preparation
and Submission
Contract Preparation and Budget
Development/Negotiation
Study Preparation and Set-up: pre
enrollment
Pharmacy Preparation and Set-up
Site Initiation
Ongoing Financial Oversight including
registration and scheduling, invoicing,
and monthly/study conclusion financial
reconciliation
Total Non-refundable Start-up Fees

Comments

$2,400.00
$500.00
$240.00

PI
variable cost
Medical
Director
variable cost
Department variable cost

Cost per
Hour

Total
Hours

60.00

40

250.00
60.00

2
4

$960.00

PI

variable cost

60.00

16

$440.00

Finance

variable cost

55.00

8

$2,400.00
PI
variable cost
$120.00
Pharmacy variable cost
$240.00 Department variable cost

60.00
60.00
60.00

40
2
4

$660.00
$7,960.00

Finance

variable cost

55.00

12

PI

10% Time
and Effort of
Base Salary
Direct fixed
cost

60.00

166

Principal Investigator
This fee is to be paid immediately
upon receipt.

Study management and Oversight
On-Going Regulatory Fees
Performed by the PI
These fees are to be paid
immediately upon receipt of invoice.

$9,960.00

Fees may vary depending on IRB used
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Regulatory Fees
Annual Reviews- Preparation and
Submission
Changes to Research (each item billed
separately)
1. Protocol Amendment/Revisions
2. Consent Form Modifications
3. New or Updated
Recruitment/Retention Materials
4. Other Changes to Research
Requiring Board Review
Adverse Event Report Submission
Local SAE Reporting
Study Close Out with IRB
Monitor Visit Fee (per visit)
Meetings And Conferences Invoiced
Fees
Investigator/ Coordinator Meetings
(Investigator)-including travel time
Conference Calls- (Investigator)

$480.00

PI

variable cost

60.00

8

$240.00
$120.00

PI
PI

variable cost
variable cost

60.00
60.00

4
2

$120.00

PI

variable cost

60.00

2

$120.00
$120.00
$120.00
$120.00
$240.00

PI
PI
PI
PI
PI

variable cost
variable cost
variable cost
variable cost
variable cost

60.00
60.00
60.00
60.00
60.00

2
2
2
2
4

$480.00
$60.00

variable cost
variable cost

60.00
60.00

8
1

$100.00
per
retrieval
$75.00
per hour

Fixed Cost

100.00

1

Fixed Cost

75.00

1

Other Fees:
Query fees will be invoiced by site
following conclusion of activity.
Storage box request fee (after final
study close out visit)
Query request fee per hour (after final
study close out visit)
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Per Patient Budget
Schedule of
Activities
Study Costs

Cost per
Unit

Service

Single
Study
Visit

Comments

Cost
per
Hour

Total
Hours

Direct fixed
cost
Direct fixed
cost
Direct fixed
cost
Direct fixed
cost

60.00

0.5

60.00

0.25

*

*

Direct fixed
cost

*

*

Direct fixed
cost
Direct fixed
cost
Direct fixed
cost
Direct fixed
cost

119.00

CLINICAL
SERVICES:
Informed Consent

30.00

PI

x

Inclusion/Exclusion

15.00

PI

x

Vital Signs

30.00

Nurse
Assistant
Nurse
Assistant

x

Nurse
Assistant

x

Height and Weight

Pulse Oximetry
Testing
Spirometry
Medical, Surgical
History
Physical ExamBrief
Skin Prick Testing

Skin Prick Test
Recording

Adverse Event
Collection
Concomitant
Medication
Collection
LABORATORY
TESTS
Review previous
RAST testing
Questionnaires:
Source Document

included
on VS
charge *
included
in VS
charge *
119.00

x

15.00

PI

x

15.00

PI

x

408.00

SPT
Operator

x

included
in SPT
charge
above **
15.00

SPT
Operator

x

Direct fixed
cost

PI

x

15.00

PI

x

30.00

PI

x

30.00

PI

30.00

60.00

0.25

60.00

0.25

408.00

**

34.00
x 12
tests
**

Direct fixed
cost
Direct fixed
cost

60.00

0.25

60.00

0.25

Direct fixed
cost

60.00

0.5

Direct fixed

60.00

0.5
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cost
Pharmacy:
SPT Tray
Dispensing- per
dispense
SPT Tray
Accountability- per
dispense

44.00

Pharmacy

x

Direct fixed
cost

44.00

1

44.00

Pharmacy

x

Direct fixed
cost

44.00

1

Patient

none

N/A

none

156.00

Facility

x

Direct fixed
cost

156.00

1

18.00

SPT
Operator
PI

x

Direct fixed
cost
Direct fixed
cost

18.00

1

60.00

1

Patient Expense
Patient Expense
(parking, stipend)
Facility Fee:
Clinic Visit (facility fee)
Study Personnel
Costs:
SPT Operator
Principal
Investigator
Additional
Personnel
Total Per Patient
Direct Cost
Total Study 26%
Indirect Cost
Total Per Patient
Cost
Total Study CostEnrolling 68
Patients

60.00

x

other

23.23
%

68
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Fixed

Vari
able

200.00

0.00

0.00

0.00

IRB Fees
Fixed Costs
Variable
Costs
Non-Refundable Startup Costs
Fixed Costs
Variable
Costs
Per Patient Budget- Total Study
Fixed Costs

9,960.00
7,96
0.00
70,992.00

Variable
Costs

Sub Total
Total Study Costs

81,152.00

16,4
91.4
4
24,4
51.4
4

105,603.44

In the clinical setting, SPT has a direct cost of 34.00 per prick.
Once the study is complete, the costs will be offset
when 3106 SPT are complete
On average each patient has 20 SPT at a given visit,
taking approximately 155 patients to recoup costs.
On average, there are 50 patients each week requiring SPT
Time in weeks to recover costs

34.00
3,106
20
155
50
3

direct
cost per
SPT
clinical SPT
SPT per patient
patients to offsite
study costs
patients/week
weeks
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Appendix C
State of Colorado Proclamation
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Appendix D
Facility Institutional Review Board Approval Letter
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Appendix E
Regis University Institutional Review Board Approval Letter
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303-964-5528 FAX
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uNIVERSITY
IRB- RfGIS L'IIVERSITY

Jul) 23.2014

Eli~beth

Lsterl
1400 Jackson Street
Den' cr. CO 80206
RE:

IRll #: 14-236

Dear Dr. bterl:
Your application to the R<-gis IRil for )OUr project... Reducing Variabihty among Multo pie
Operators Using a Si ngle Technique and Device for Skin Prick Testing in Child ren." \\US
approved as an exp..'llited stud) on Jul) 18. 2014. It is appro\ed per OHRP CategOI) of Research
#Ill.
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subjects from that \\hich "as appro,ed in the named application. the ne\\ research plan must be
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staning date require IRB continuation"" ic\\. The continuation ;hould be requested 30 da)s
prior to the one )Car anni, crsai) date of the appro,cd project's stan date. A completion report of
the linding> of this stud) should be sent to the IRI3.
In addition. it is the rcsponsibilit) of the principal ill\CStigntor to prompt!) rcpon to the IRil any
injuries to human subjects and;or an) unanticipated proble ms \\ithin the scope of the apprO\ed
research \\hich rna) pose ris~ to human ;ubjects. I astl). a final rcpon >hould be submitted at
completion of the project and it b the responsibility of the investigator to tnaintain signed
cono;cnt documents for a period of three ) cars after the conclusion of the research.

Sincere!).

CVu..t~~
Patsy McGuire Cullen. PhD. P\JP-BC
Chair. Institutional Re' ic" Board
Professor & Director
Doctor of Nursing Practice & Nurse Practitioner Programs
Loretto lleights School ofl\ursing
Regis Unh-crsit)
cc. Dr. Em in Gelfand

A JESUIT UNIVERSITY
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o.nv.r Cotot8do 80221·1099
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Appendix F
National Jewish Health Letter of Support
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Appendix G
Research Study Forms
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rri•c::ipal la\'tifiptor: Pia Haut. MD
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Other people in this study
Up to 68 local subjects with will be enrolled in this research study at National Jewish Health.
This study will not done at any other clinic or hospital. Taking part in this study is completely
voluntary. You do not have to participate if you don't want to. You may also leave the study at
any time. If you leave the study before it is finished, there will be no penalty to you, and you
will not lose any benefits to which you are otherwise entitled.
What happens if I join this study?
If you agree to join the study, you will be asked to sign this form. Next the following information
will be obtained during the single study visit:
Enrollment/Study Visit 1
1. Demographics: age at entry, date of birth, gender, race/ethnicity.
2. Clinical Presentation: brief history of allergic symptoms, signs, age at onset, initial
interventions
3. Current Medications and Diet History
4. Brief Physical examination: Measurements: vital signs; Appearance: skin assessment;
5. Skin Prick Tests: using Duotip prick, Duotip twist techniques and Quintip punch
technique. A total of 12 skin prick tests will be completed on your back and recorded 15
minutes later. Each device will be tested using two histamine solutions (positive control
and expected to react during test) and two glycerol-saline solutions (negative control and
expected to not react during test), in three vertical columns and spaced equally apart. The
operator and person recording the result will not know what solution has been placed
where. This is called being "blinded" to the test.
Table - Study Visit
The single study visit will include the following:
EVALUATION

VISIT 1

Informed Consent

X

Eligibility

X

Medical History

X

Medication History

X

Brief Physical Examination

X

Skin Prick Tests

X

Once the skin prick tests are completed, your participation in the study is complete. The duration of
the study visit will last approximately 30 minutes and the 12 skin prick tests will take less than 2
minutes to complete and recorded 15 minutes later.
What are the possible discomforts or risks?
Discomforts you may experience while in this study include brief minimal localized site pain is
associated with the skin prick test procedure which will resolve immediately without treatment
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once the prick is completed. No additional treatment is necessary to resolve pain. Histamine
solution (10 mg/mL; Hollister-Stier, Spokane, Wash) as the positive control will cause itching at
the site. After recording the results after 15 minutes, your back will be washed with warm water
and the itching should resolve quickly without further treatment.
There is a potential risk of loss of confidentiality, but we will do everything to maintain the
confidentiality of your personal information by keeping all research records and results in a
locked file cabinet within a locked office of the principal investigator. However, confidentiality
cannot be guaranteed.
The study may include risks that are unknown at this time.
What are the possible benefits of the study?
This study is designed for the researcher to learn more about the two skin prick test devices and
the three different ways that we use them.
This study is not designed to treat any illness or to improve your health. Also, there may be
risks, as discussed in the section describing the discomforts or risks.
Are there alternative treatments?
You may elect to not participate in the study.
The treating clinician may be both your health care provider and the investigator for this study.
This clinician is interested both in your clinical welfare and in the conduct of this study. Before
entering this study, or at any time during the study, you may ask for a second opinion about your
care from another clinician who is not associated in any way with the study.
Will I be paid for being in the study?
You will not be paid to be in the study.
Will I have to pay for anything?
It will not cost you anything to be in the study.
Is my participation voluntary?
Taking part in this study is voluntary. You have the right to choose not to take part in this study.
If you choose to take part, you have the right to stop at any time. If you refuse or decide to
withdraw later, you will not lose any benefits or rights to which you are entitled.
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What happens if I am injured or hurt during the study?
In the event of an injury or illness resulting from your participation in this research study, your
study doctor will assist you in receiving appropriate health care, including first aid, emergency
treatment and follow-up care either at National Jewish Health or another appropriate health care
facility. If medical costs are incurred, your insurance company may be billed. In accordance with
general policy, National Jewish Health makes no commitment to provide free medical care of
compensation for injury or illness resulting from your participation in this study. By signing this
form you have not given up your legal rights. For further information, please contact Pia Hauk,
MD or Elizabeth Esterl DNP, RN, investigators for this study. They can be reached at phone
number is 303-398-1239.
If you believe you have experienced any study related illness, adverse event, or injury, you must
notify the study doctor as soon as possible.
This has been explained to me and all my questions have been answered
______

Subject/ Parent/Legal Guardian Initials

Who do I call if I have questions?
The researchers carrying out this study are Pia Haul, MD and Elizabeth Esterl DNP, RN. You
may ask any questions you have now. If you have questions, concerns, or complaints later, you
may call Dr. Hauk or Elizabeth Esterl at 303-398-1239. You will be given a copy of this form to
keep.
You may have questions about your rights as someone in this study. You can call Dr. Hauk or
Elizabeth Esterl with questions. You can also call the responsible Institutional Review Boards at
National Jewish Health and Regis University. You can call them at 303-398-1477 (NJH) and
303-934-3616 (Regis University) or email Regis University IRB at IRB@regis.edu.
Who will see my research information?
National Jewish Health and Regis University have rules to protect information about you.
Federal and state laws including the Health Insurance Portability and Accountability Act
(HIPAA) also protect your privacy. This part of the consent form tells you what information
about you may be collected in this study and who might see or use it.
The institutions involved in this study include:
 National Jewish Health
 Regis University
We cannot do this study without your permission to see, use and give out your information. You
do not have to give us this permission. If you do not, then you may not join this study.
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We will see, use and disclose your information only as described in this form and in our Notice
of Privacy Practices; however, people outside National Jewish Health and Regis University may
not be covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information but
confidentiality cannot be guaranteed. At minimum, we will remove identifying data and use
coding for your information. We will also keep your records in a locked office. All records
relating to research that is conducted will be retained for at least three years after completion of
the research.
The use and disclosure of your information has no time limit. You can cancel your permission to
use and disclose your information at any time by writing to the study’s Principal Investigator
(PI), at the name and address listed below. If you do cancel your permission to use and disclose
your information, your part in this study will end and no further information about you will be
collected. Your cancellation would not affect information already collected in this study.
Pia Hauk, MD
Elizabeth Esterl DNPc, RN
Principal Investigator
Co-Investigator
National Jewish Health- NJ4Kids Program
1400 Jackson Street A220
Denver, Colorado 80206
303-398-1239
Both the research records that identify you and the consent form signed by you may be looked at
by others who have a legal right to see that information, such as:
 Federal offices such as the Food and Drug Administration (FDA) and the Office of
Human Research Protections (OHRP) that protect research subjects like you.
 The Institutional Review Boards that are responsible for overseeing this research
 The principal investigator and study team associated with this study.
 Officials at the institution where the research is conducted and officials at other
institutions involved in this study who are in charge of making sure that we follow all of
the rules for research
We might talk about this research study at meetings. We might also print the results of this
research study in relevant journals. But we will always keep the names of the research subjects,
like you, private.
You have the right to request access to your personal health information from the Investigator.
Information about you that will be seen, collected, used and disclosed in this study:
 Name and Demographic Information (age, sex, ethnicity, address, phone number, etc.
 Portions of your previous and current Medical Records that are relevant to this study,
including but not limited to Diagnosis (es), History and Physical, Medication History,
Diet History, Laboratory Results, Skin Prick Test results
 Research Visit and Research Test record
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What happens to Data that is collected is collected in this study?
Coded data collected in this study will be stored in a secure, password protected research
database. If you decide to withdraw from this study, data collected up to this time will be kept
and used for analysis.
Agreement to be in this study and use my data
I have read and initialed each page of this informed consent and HIPAA authorization form (or it
was read to me). I was informed about the possible risks and benefits of being in this study. I
know that being in this study is voluntary. I choose to be in this study. I know I can stop being
in this study at any time. I will get a copy of this form after it is signed.
Patient Signature:

Date:

Print Name: ________________________________________________________

______________________________________________
Date_________
Parent/Legally Authorized Representative/ Proxy Decision Maker Signature

Print Name: __________________________________________________________

___________________________________________________
Consent form explained by: Signature

Date: ________

Print Name: _____________________________________________________
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Can I ask Questions?
I can ask questions about the study now. These questions will be answered now. If I think of
any questions later, I’ll be able to ask them too. I will get answers to those questions as well.
If I want to, I can call:
Pia Hauk, MD
Principal Investigator

Elizabeth Esterl DNPc, RN
Co-Investigator
National Jewish Health- NJ4Kids Program
1400 Jackson Street
Denver, Colorado 80204
303-398-1239

Do I Have to Do This?
I know that I do not have to be in this study. No one will be mad at me if I say no.
I want to be in the study at this time.  YES

 NO

I will get a copy of this form to keep.

Child’s Printed Name:___________________________________________________
Child’s Signature:________________________________________Date__________

Parent/Legal Guardian Printed Name:_____________________________________
Parent/Legal Guardian Signature:__________________________ Date__________

I have explained the research at a level that is understandable by the child and believe that
the child understands what is expected during this study.

Printed Name of Person Obtaining Assent__________________________________

Signature of Person Obtaining Assent:________________________Date:__________
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Duotip (Lincoln Diagnostics) bifurcated plastic needle using twist technique
Quintip (Hollister-Stier) steel lancet using punch technique

Other people in this study
Up to 68 local subjects with will be enrolled in this research study at National Jewish Health.
This study will not be done at any other clinic or hospital. Taking part in this study is completely
voluntary. You do not have to participate if you don't want to. You may also leave the study at
any time. If you leave the study before it is finished, there will be no penalty to you, and you
will not lose any benefits to which you are otherwise entitled.
What happens if I join this study?
If you agree to join the study, you will be asked to sign this form. Next, the following
information will be obtained during the single study visit:
Enrollment/Study Visit 1
6. Demographics: age at entry, date of birth, gender, race/ethnicity.
7. Clinical Presentation: brief history of allergic symptoms, signs, age at onset, initial
interventions
8. Current Medications and Diet History
9. Brief Physical examination: Measurements: vital signs; Appearance: skin assessment;
10. Skin Prick Tests: using Duotip prick, Duotip twist techniques and Quintip punch
technique. A total of 12 skin prick tests will be completed on your back and recorded 15
minutes later. Each device will be tested using two histamine solutions (positive control
and expected to react during test) and two glycerol-saline solutions (negative control and
expected to not react during test), in three vertical columns and spaced equally apart. The
operator and person recording the result will not know what solution has been placed
where. This is called being "blinded" to the test.
Table - Study Visit
The single study visit will include the following:
EVALUATION

VISIT 1

Informed Consent

X

Eligibility

X

Medical History

X

Medication History

X

Brief Physical Examination

X

Skin Prick Tests

X

Once the skin prick tests are completed, your participation in the study is complete. The duration of
the study visit will last approximately 30 minutes and the 12 skin prick tests will take less than 2
minutes to complete and recorded 15 minutes later.
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What are the possible discomforts or risks?
Discomforts you may experience while in this study include brief minimal localized site pain is
associated with the skin prick test procedure which will resolve immediately without treatment
once the prick is completed. No additional treatment is necessary to resolve pain. Histamine
solution (10 mg/mL; Hollister-Stier, Spokane, Wash) as the positive control will cause itching at
the site. After recording the results after 15 minutes, your back will be washed with warm water
and the itching should resolve quickly without further treatment.
There is a potential risk of loss of confidentiality, but we will do everything to maintain the
confidentiality of your personal information by keeping all research records and results in a
locked file cabinet within a locked office of the principal investigator. However, confidentiality
cannot be guaranteed.
The study may include risks that are unknown at this time.
What are the possible benefits of the study?
This study is designed for the researcher to learn more about the two skin prick test devices and
the three different ways that we use them.
This study is not designed to treat any illness or to improve your health. Also, there may be
risks, as discussed in the section describing the discomforts or risks.
Are there alternative treatments?
You may elect to not participate in the study.
The treating clinician may be both your health care provider and the investigator for this study.
This clinician is interested both in your clinical welfare and in the conduct of this study. Before
entering this study, or at any time during the study, you may ask for a second opinion about your
care from another clinician who is not associated in any way with the study.
Will I be paid for being in the study?
You will not be paid to be in the study.
Will I have to pay for anything?
It will not cost you anything to be in the study.
Is my participation voluntary?
Taking part in this study is voluntary. You have the right to choose not to take part in this study.
If you choose to take part, you have the right to stop at any time. If you refuse or decide to
withdraw later, you will not lose any benefits or rights to which you are entitled.
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What happens if I am injured or hurt during the study?
In the event of an injury or illness resulting from your participation in this research study, your
study doctor will assist you in receiving appropriate health care, including first aid, emergency
treatment and follow-up care either at National Jewish Health or another appropriate health care
facility. If medical costs are incurred, your insurance company may be billed. In accordance with
general policy, National Jewish Health makes no commitment to provide free medical care of
compensation for injury or illness resulting from your participation in this study. By signing this
form you have not given up your legal rights. For further information, please contact Pia Hauk,
MD or Elizabeth Esterl DNPc, RN, investigators for this study. They can be reached at phone
number 303-398-1239.
If you believe you have experienced any study related illness, adverse event, or injury, you must
notify the study doctor as soon as possible.
This has been explained to me and all my questions have been answered
______

Subject/ Parent/Legal Guardian Initials

Who do I call if I have questions?
The researchers carrying out this study are Pia Hauk, MD and Elizabeth Esterl DNPc, RN. You
may ask any questions you have now. If you have questions, concerns, or complaints later, you
may call Dr. Hauk or Elizabeth Esterl at 303-398-1239. You may also call Dr. Diane Ernst,
Regis University, DNP student project advisor for co-investigator, Elizabeth Esterl at 303-9645768 or dernst@regis.edu.
You may have questions about your rights as someone in this study. You can call Dr. Hauk or
Elizabeth Esterl with questions. You can also contact the responsible Institutional Review
Boards (IRB) at National Jewish Health and Regis University. You can call the National Jewish
Health IRB at 303-398-1477 and/or Regis University IRB at 303-458-4206 or email at
irb@regis.edu.
Who will see my research information?
National Jewish Health and Regis University have rules to protect information about you.
Federal and state laws including the Health Insurance Portability and Accountability Act
(HIPAA) also protect your privacy. This part of the consent form tells you what information
about you may be collected in this study and who might see or use it.
The institutions involved in this study include:
 National Jewish Health
 Regis University, Denver, Colorado
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We cannot do this study without your permission to see, use and give out your information. You
do not have to give us this permission. If you do not give us your permission, then you may not
join this study.
We will see, use and disclose your information only as described in this form and in our Notice
of Privacy Practices; however, people outside National Jewish Health and Regis University may
not be covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information but
confidentiality cannot be guaranteed. At minimum, we will remove identifying data and use
coding for your information. We will also keep your records in a locked office. All records
relating to research that is conducted will be retained for at least three years after completion of
the research.
The use and disclosure of your information has no time limit. You can cancel your permission to
use and disclose your information at any time by writing to the study’s Principal Investigator
(PI), at the name and address listed below. If you do cancel your permission to use and disclose
your information, your part in this study will end and no further information about you will be
collected. Your cancellation would not affect information already collected in this study.
Pia Hauk, MD
Elizabeth Esterl DNPc, RN
Principal Investigator
Co-Investigator
National Jewish Health- NJ4Kids Program
1400 Jackson Street A220
Denver, Colorado 80206
303-398-1239
Both the research records that identify you and the consent form signed by you may be looked at
by others who have a legal right to see that information, such as:
 Federal offices such as the Food and Drug Administration (FDA) and the Office of
Human Research Protections (OHRP) that protect research subjects like you.
 The Institutional Review Boards that are responsible for overseeing this research
 The principal investigator and study team associated with this study.
 Officials at the institution where the research is conducted and officials at other
institutions involved in this study who are in charge of making sure that we follow all of
the rules for research
We might talk about this research study at meetings. We might also print the results of this
research study in relevant journals. However, we will always keep the names of the research
subjects, like you, private.
You have the right to request access to your personal health information from the Investigators.
Information about you that will be seen, collected, used and disclosed in this study:
 Name and Demographic Information (age, sex, ethnicity, address, phone number, etc.)

78



Portions of your previous and current Medical Records that are relevant to this study,
including but not limited to Diagnosis (es), History and Physical, Medication History,
Diet History, Laboratory Results, Skin Prick Test results
Research Visit and Research Test record

What happens to data that is collected in this study?
Coded data collected in this study will be stored in a secure, password protected research
database. If you decide to withdraw from this study, data collected up to this time will be kept
and used for analysis.
Agreement to be in this study and use my data
I have read and initialed each page of this informed consent and HIPAA authorization form (or it
was read to me). I was informed about the possible risks and benefits of being in this study. I
know that being in this study is voluntary. I choose to be in this study. I know I can stop being
in this study at any time. I will get a copy of this form after it is signed.
Patient Signature:

Date:

Print Name: ________________________________________________________

______________________________________________

Date_________

Parent/Legally Authorized Representative/ Proxy Decision Maker Signature
Print Name: __________________________________________________________

___________________________________________________

Date: ________

Consent form explained by: Signature
Print Name: _____________________________________________________
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________________________________________________________________________
Informed Consent Verification
a. Was the subject provided ample time and opportunity to inquire about the details of the
study?
[ ] Yes
[ ] No
b. Were all questions about the trial answered to the satisfaction of the subject?
[ ] Yes
[ ] No
c. Was written Informed Consent obtained prior to study participation?
[]
Yes
[ ] No
d. Was a signed copy given to the subject’s parent/legal guardian?
[ ] Yes
[ ] No

Signature of person reviewing the informed consent and study information with the
subject:_________________________________________________________________
________________________________________________________________________
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STUDY VISIT - DATE_________________________
INCLUSION CRITERIA:
[ ] Age 1 year to 16 years of either sex and any race
[ ] English speaking
[ ] Medications, including but not limited to antihistamines, withheld for appropriate time period
as per hospital protocol
EXCLUSION CRITERIA
[ ] Inability to comply with skin prick testing
[ ] Failure of the family/patient to sign the informed consent and HIPAA authorization form

Patient has met all inclusion & exclusion criteria?
DEMOGRAPHIC DATA:
Date of Birth_____________________
Race: [ ] Caucasian
[ ] Black

[ ]Asian
[ ] Other –Specify

Ethnicity: [ ] Hispanic

[ ] Non-Hispanic

Sex:

[ ] Female

[ ] Male

WEIGHT: ____________________kilograms
HEIGHT: ____________________centimeters

[ ] Not Done
[ ] Not Done

[ ] Yes

[ ] No
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SIGNIFICANT MEDICAL HISTORY FOR ALLERGIC DISEASE
[ ] Asthma
[ ] Food Allergy
Food Name
Type of Reaction
1. _________________________________________________________________
2. _________________________________________________________________
3. _________________________________________________________________
4. _________________________________________________________________
5. _________________________________________________________________
6. _________________________________________________________________
7. _________________________________________________________________
8. _________________________________________________________________
9. _________________________________________________________________
10. _________________________________________________________________
[ ] Drug Allergy
DRUG ALLERGIES:
Drug Name/ Class
Type of Reaction
11. _________________________________________________________________
12. _________________________________________________________________
13. _________________________________________________________________
14. _________________________________________________________________
15. _________________________________________________________________
16. _________________________________________________________________
17. _________________________________________________________________
18. _________________________________________________________________
19. _________________________________________________________________
20. _________________________________________________________________
[ ] Environmental Allergy
ENVIRONMENTAL ALLERGIES:
Environmental Allergy
Type of Reaction
21. _________________________________________________________________
22. _________________________________________________________________
23. _________________________________________________________________
24. _________________________________________________________________
25. _________________________________________________________________
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SIGNIFICANT MEDICAL HISTORY
[ ] Not done
[ ] No significant medical history
DISEASE SYNDROME – SPECIFY
Non Drug Allergies (specify substance & manifestations)
1.___________________________ [ ] past
[ ] present
2.___________________________ [ ] past
[ ] present
3.___________________________ [ ] past
[ ] present
4.___________________________ [ ] past
[ ] present
5.___________________________ [ ] past
[ ] present
6.___________________________ [ ] past
[ ] present
7.___________________________ [ ] past
[ ] present
8.___________________________ [ ] past
[ ] present
9.___________________________ [ ] past
[ ] present
10.___________________________ [ ] past
[ ] present
11.___________________________ [ ] past
[ ] present
12.___________________________ [ ] past
[ ] present
13.___________________________ [ ] past
[ ] present
14.___________________________ [ ] past
[ ] present
15.___________________________ [ ] past
[ ] present

PERTINENT DETAILS
Include surgeries/dates
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
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PHYSICAL EXAMINATION:
[ ] Not done
[ ] Not required at this visit as per protocol
Date (dd/MMM/yyyy): _ _/_ _ _/ _ _ _ _
Site
General Appearance

Head

Lungs

Heart

Abdomen

Skin

Describe Abnormalities
[ ] Normal
[ ] Abnormal
[ ] Not Done
[ ] Normal
[ ] Abnormal
[ ] Not Done
[ ] Normal
[ ] Abnormal
[ ] Not Done
[ ] Normal
[ ] Abnormal
[ ] Not Done
[ ] Normal
[ ] Abnormal
[ ] Not Done
[ ] Normal
[ ] Abnormal
[ ] Not Done
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SKIN PRICK TESTSOperator: _____________________________________________________________
[ ] Not done
Tray used:

Date (dd/MMM/yyyy): _ _/_ _ _/ _ _ _ _
[]A

[]B

[]C

Reading left for right when looking at patient's back:
Column 1- [ ] Duotip Prick Lift
[ ] Quintip Punch
[ ] Duotip Twist
Column 2- [ ] Duotip Prick Lift
[ ] Quintip Punch
[ ] Duotip Twist
Column 3- [ ] Duotip Prick Lift
[ ] Quintip Punch
[ ] Duotip Twist
DO NOT REVEAL INFORMATION REGARDING TECHNIQUE USED TO ANYONE
15 minutes timer started_________________________________________ (time)
Comments on causes of clinically significant abnormalities:

CONCOMITANT MEDICATION RECORD:
[ ] Not done
[ ] None
Drug Name
Indication
Route

Daily Dose

Dates Taken

Prestudy
YES
NO
[ ] Yes
[ ] Yes
[ ] Yes
[ ] Yes

ADVERSE EVENTS:
[ ] Not done
[ ] None
Adverse Event
Relationship to
Skin Prick Test

Grade

Start

Stop

[ ] No
[ ] No
[ ] No
[ ] No

Action Taken
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Skin Prick Test Result Form
Recorder:_______________________________________________________________
Time: ______________________________skin prick test results recorded.
When looking at the participant's back
Solution
Column 1
Top to Bottom
Left
1
wheal:

2

3

4

Column 2
Middle
wheal:

Column 3
Right
wheal:

_______ x _______

_______ x _______

_______ x _______

erythema:

erythema:

erythema:

_______ x _______

_______ x _______

_______ x _______

wheal:

wheal:

wheal:

_______ x _______

_______ x _______

_______ x _______

erythema:

erythema:

erythema:

_______ x _______

_______ x _______

_______ x _______

wheal:

wheal:

wheal:

_______ x _______

_______ x _______

_______ x _______

erythema:

erythema:

erythema:

_______ x _______

_______ x _______

_______ x _______

wheal:

wheal:

wheal:

_______ x _______

_______ x _______

_______ x _______

erythema:

erythema:

erythema:

_______ x _______

_______ x _______

_______ x _______
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COORDINATOR COMMENTS
[ ] Not done
Date (dd/MMM/yyyy): _ _/_ _ _/ _ _ _ _
Time of contact (24 hour clock) _ _: _ _
Comments;____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Visit completed by _______________________ Date___________________

